Literature DB >> 19234124

Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.

Sarah Nicholls1, Karen P Piper, Fiyaz Mohammed, Timothy R Dafforn, Stefan Tenzer, Mahboob Salim, Premini Mahendra, Charles Craddock, Peter van Endert, Hansjörg Schild, Mark Cobbold, Victor H Engelhard, Paul A H Moss, Benjamin E Willcox.   

Abstract

T cell recognition of minor histocompatibility antigens (mHags) underlies allogeneic immune responses that mediate graft-versus-host disease and the graft-versus-leukemia effect following stem cell transplantation. Many mHags derive from single amino acid polymorphisms in MHC-restricted epitopes, but our understanding of the molecular mechanisms governing mHag immunogenicity and recognition is incomplete. Here we examined antigenic presentation and T-cell recognition of HA-1, a prototypic autosomal mHag derived from single nucleotide dimorphism (HA-1(H) versus HA-1(R)) in the HMHA1 gene. The HA-1(H) peptide is restricted by HLA-A2 and is immunogenic in HA-1(R/R) into HA-1(H) transplants, while HA-1(R) has been suggested to be a "null allele" in terms of T cell reactivity. We found that proteasomal cleavage and TAP transport of the 2 peptides is similar and that both variants can bind to MHC. However, the His>Arg change substantially decreases the stability and affinity of HLA-A2 association, consistent with the reduced immunogenicity of the HA-1(R) variant. To understand these findings, we determined the structure of an HLA-A2-HA-1(H) complex to 1.3A resolution. Whereas His-3 is accommodated comfortably in the D pocket, incorporation of the lengthy Arg-3 is predicted to require local conformational changes. Moreover, a soluble TCR generated from HA-1(H)-specific T-cells bound HA-1(H) peptide with moderate affinity but failed to bind HA-1(R), indicating complete discrimination of HA-1 variants at the level of TCR/MHC interaction. Our results define the molecular mechanisms governing immunogenicity of HA-1, and highlight how single amino acid polymorphisms in mHags can critically affect both MHC association and TCR recognition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19234124      PMCID: PMC2656175          DOI: 10.1073/pnas.0900411106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique.

Authors:  R A Pierce; E D Field; J M den Haan; J A Caldwell; F M White; J A Marto; W Wang; L M Frost; E Blokland; C Reinhardus; J Shabanowitz; D F Hunt; E Goulmy; V H Engelhard
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

2.  TCR binding to peptide-MHC stabilizes a flexible recognition interface.

Authors:  B E Willcox; G F Gao; J R Wyer; J E Ladbury; J I Bell; B K Jakobsen; P A van der Merwe
Journal:  Immunity       Date:  1999-03       Impact factor: 31.745

Review 3.  Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire.

Authors:  Victor H Engelhard; Anthony G Brickner; Angela L Zarling
Journal:  Mol Immunol       Date:  2002-10       Impact factor: 4.407

Review 4.  Molecules and mechanisms of the graft-versus-leukaemia effect.

Authors:  Marie Bleakley; Stanley R Riddell
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

5.  The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides.

Authors:  S Buus; A Sette; S M Colon; C Miles; H M Grey
Journal:  Science       Date:  1987-03-13       Impact factor: 47.728

6.  A sequential model for peptide binding and transport by the transporters associated with antigen processing.

Authors:  P M van Endert; R Tampé; T H Meyer; R Tisch; J F Bach; H O McDevitt
Journal:  Immunity       Date:  1994-09       Impact factor: 31.745

7.  HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides.

Authors:  D N Garboczi; D T Hung; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

8.  Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice.

Authors:  L Hambach; B A Nijmeijer; Z Aghai; M L J van Schie; M H M Wauben; J H F Falkenburg; E Goulmy
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

Review 9.  Pathophysiology of acute graft-versus-host disease.

Authors:  Pavan Reddy
Journal:  Hematol Oncol       Date:  2003-12       Impact factor: 5.271

10.  Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion.

Authors:  Brigitte Kircher; Stefan Stevanovic; Martina Urbanek; Andrea Mitterschiffthaler; Hans-Georg Rammensee; Kurt Grünewald; Günther Gastl; David Nachbaur
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

View more
  17 in total

1.  Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction.

Authors:  Amy A Simpson; Fiyaz Mohammed; Mahboob Salim; Amy Tranter; Alan B Rickinson; Hans J Stauss; Paul A H Moss; Neil M Steven; Benjamin E Willcox
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.

Authors:  Marie Bleakley; Cameron J Turtle; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2012-08       Impact factor: 2.929

3.  Pan-Specific Prediction of Peptide-MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity.

Authors:  Michael Rasmussen; Emilio Fenoy; Mikkel Harndahl; Anne Bregnballe Kristensen; Ida Kallehauge Nielsen; Morten Nielsen; Søren Buus
Journal:  J Immunol       Date:  2016-07-08       Impact factor: 5.422

4.  Trophoblast expression of the minor histocompatibility antigen HA-1 is regulated by oxygen and is increased in placentas from preeclamptic women.

Authors:  C Linscheid; E Heitmann; P Singh; E Wickstrom; L Qiu; H Hodes; T Nauser; M G Petroff
Journal:  Placenta       Date:  2015-06-06       Impact factor: 3.481

5.  Importance of genetic background for risk of relapse shown in altered prefrontal cortex gene expression during abstinence following chronic alcohol intoxication.

Authors:  J G Hashimoto; M R Forquer; M A Tanchuck; D A Finn; K M Wiren
Journal:  Neuroscience       Date:  2010-11-25       Impact factor: 3.590

Review 6.  Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.

Authors:  Marie Bleakley; Stanley R Riddell
Journal:  Immunol Cell Biol       Date:  2011-02-08       Impact factor: 5.126

Review 7.  Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy.

Authors:  Caitlin Linscheid; Margaret G Petroff
Journal:  Am J Reprod Immunol       Date:  2013-02-08       Impact factor: 3.886

Review 8.  Peptide mimotopes alter T cell function in cancer and autoimmunity.

Authors:  Jill E Slansky; Maki Nakayama
Journal:  Semin Immunol       Date:  2020-03-20       Impact factor: 11.130

Review 9.  Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT.

Authors:  Edus H Warren; Xinyi Cindy Zhang; Shuying Li; Wenhong Fan; Barry E Storer; Jason W Chien; Michael J Boeckh; Lue Ping Zhao; Paul J Martin; John A Hansen
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

10.  Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.

Authors:  Yishai Ofran; Haesook T Kim; Vladimir Brusic; Loren Blake; Michael Mandrell; Catherine J Wu; Stefanie Sarantopoulos; Roberto Bellucci; Derin B Keskin; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.